PHA 568487
Modify Date: 2025-09-01 20:29:06
PHA 568487 structure
|
Common Name | PHA 568487 | ||
|---|---|---|---|---|
| CAS Number | 527680-57-5 | Molecular Weight | 404.41400 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H24N2O7 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PHA 568487PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR)[1][2].PHA 568487 reduces neuroinflammation and oxidative stress[2]. PHA-568487 has rapid brain penetration[3]. |
| Name | PHA-568487 fumarate |
|---|---|
| Synonym | More Synonyms |
| Description | PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR)[1][2].PHA 568487 reduces neuroinflammation and oxidative stress[2]. PHA-568487 has rapid brain penetration[3]. |
|---|---|
| Related Catalog | |
| In Vitro | PHA 568487 increases anti-oxidant gene expression and decreases oxidative stress and phosphorylation of NF-κb p65. Methyllycaconitine (MLA) has the opposite effects[2]. PHA increases anti-oxidant genes and NADPH oxidase expression associated with decreased phosphorylation of NF-kB p65 in microglia/macrophages[3]. |
| In Vivo | PHA 568487 attenuates neuronal injury and behavioral dysfunction in mice with ischemic stroke only and ischemic stroke plus tibia fracture[2]. PHA 568487 (1.25 mg/kg; i.p.; treated daily)-treated ischemic rats shows a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome[4]. Animal Model: C57BL/6J male mice (10-12 weeks old)[2] Dosage: PHA 568487 (PHA; 0.4 and 0.8 mg/kg); Methyllycaconitine (MLA; 4 and 6 mg/kg) Administration: Injected intraperitoneally once on day 1, or twice on days 1 and 2, after pMCAO Result: Injection of PHA (0.8 mg/kg) and MLA (6 mg/kg) on days 1 and 2 after pMCAO yielded the best effect on infarct volume and behavior tests. Animal Model: Adult male Sprague-Dawley rats (297 6±8.3 g)[4] Dosage: 1.25 mg/kg Administration: I.p.;0.1 mL; treated daily Result: Showed a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome. |
| References |
| Molecular Formula | C20H24N2O7 |
|---|---|
| Molecular Weight | 404.41400 |
| Exact Mass | 404.15800 |
| PSA | 125.40000 |
| LogP | 1.32240 |
| Storage condition | -20°C |
| (S)-Methylisothiourea sulfate |